Literature DB >> 19050347

Current risks in blood transfusion in Japan.

Hiroko Otsubo1, Kazunari Yamaguchi.   

Abstract

Over the past decades, the incidence of transfusion-transmitted diseases has been dramatically reduced. These reductions have been due to a multifocal approach to the collection, processing, and release of blood components. The estimated risks of transfusion-transmitted hepatitis viruses are now extremely small, but the possibility of infections with emerging pathogens always exists because preventive measures may not be available for all cases. Thus, some patients may be harmed before preventive measures are introduced. Beside transfusion-transmitted infections (TTI), unsolved residual risks such as transfusion-related acute lung injury or incompatible blood components transfusion still exist as major concerns. Continuous efforts toward research on and the prevention of adverse reaction-related blood components must be made to ensure blood safety. The purpose of this article is to introduce the concept of the current risks of transfusion including TTI, review the preventive measures already implemented, and discuss future visions for transfusion safety in Japan.

Entities:  

Mesh:

Year:  2008        PMID: 19050347

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  8 in total

Review 1.  Development of recombinant hemoglobin-based oxygen carriers.

Authors:  Cornelius L Varnado; Todd L Mollan; Ivan Birukou; Bryan J Z Smith; Douglas P Henderson; John S Olson
Journal:  Antioxid Redox Signal       Date:  2012-11-16       Impact factor: 8.401

2.  Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010.

Authors:  Moon Jung Kim; Quehn Park; Hyuk Ki Min; Hyun Ok Kim
Journal:  BMC Infect Dis       Date:  2012-07-20       Impact factor: 3.090

3.  Frequency of homologous blood transfusion in patients undergoing cleft lip and palate surgery.

Authors:  Wasiu L Adeyemo; Mobolanle O Ogunlewe; Ibironke Desalu; Akinola L Ladeinde; Titilope A Adeyemo; Bolaji O Mofikoya; Olakunle O Hassan; Alani S Akanmu
Journal:  Indian J Plast Surg       Date:  2010-01

4.  T-Cell Response to Hepatitis B Core Antigen: Identification of Prior Exposure to and Confirmatory Testing for Screening for Anti-HBc.

Authors:  Patricia Araujo; Roger Y Dodd; Flavia Latinni; Renata Souza; Ricardo Diaz; Jose Augusto Barreto
Journal:  J Biomark       Date:  2013-12-03

Review 5.  Transfusion transmitted diseases in perioperative and intensive care settings.

Authors:  Rekha Das; Upendra Hansda
Journal:  Indian J Anaesth       Date:  2014-09

6.  Is Blood Transfusion Justified During Soft Tissue Surgery in Noma Patients? A One-Year Appraisal at Noma Children Hospital, Sokoto, Nigeria.

Authors:  Mujtaba Bala; Olalere Omoyosola Gbolahan; Abdurrazaq Olanrewaju Taiwo; Ramat Oyebunmi Braimah; Adebayo Aremu Ibikunle; Muhammad Kaura Abubakar
Journal:  J West Afr Coll Surg       Date:  2022-08-27

7.  Serological surveillance development for tropical infectious diseases using simultaneous microsphere-based multiplex assays and finite mixture models.

Authors:  Yoshito Fujii; Satoshi Kaneko; Samson Muuo Nzou; Matilu Mwau; Sammy M Njenga; Chihiro Tanigawa; James Kimotho; Anne Wanjiru Mwangi; Ibrahim Kiche; Sohkichi Matsumoto; Mamiko Niki; Mayuko Osada-Oka; Yoshio Ichinose; Manabu Inoue; Makoto Itoh; Hiroshi Tachibana; Kazunari Ishii; Takafumi Tsuboi; Lay Myint Yoshida; Dinesh Mondal; Rashidul Haque; Shinjiro Hamano; Mwatasa Changoma; Tomonori Hoshi; Ken-Ichi Kamo; Mohamed Karama; Masashi Miura; Kenji Hirayama
Journal:  PLoS Negl Trop Dis       Date:  2014-07-31

8.  Serious Adverse Transfusion Reactions Reported in the National Recipient-Triggered Trace Back System in Korea (2006-2014).

Authors:  Jeong Ran Kwon; Eun Jeong Won; Hyun Jung Jo; Sae Rom Choi; Kyoungyul Lee; Sinyoung Kim; Hyeong Sik Ahn; Young Sill Choi; Duck Cho; Dong Han Lee
Journal:  Ann Lab Med       Date:  2016-07       Impact factor: 3.464

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.